Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...

Raising the dose of Novo Nordisk A/S’s obesity drug Wegovy helped patients shed more pounds in a trial while still falling ...

The list includes Novo Nordisk’s blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, ...

Mounjaro, like other GLP-1 drugs, carries potential side effects, including nausea, vomiting, dehydration, and hypoglycaemia ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

It’s taken LVMH nearly a year-and-a-half to regain its spot as Europe’s biggest stock from Novo Nordisk A/S.Most Read from ...

Apple stock rises after falling Thursday by 4%, the most since August, Qorvo stock jumps following a report that activist ...

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...